Publication | Closed Access

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

MedicinePharmacologyAdvanced Solid TumorsPi3k InhibitorPharmacotherapyOral Pan-classAnti-cancer AgentCancer TreatmentOncologyRadiation Oncology